Cremophor EL Modifies Multidrug Resistance
Author Information
Author(s): G.J. Schuurhuis, H.J. Broxterman, H.M. Pinedo, Th. H.M. van Heijningen, C.K. van Kalken, J.B. Vermorken, E.C. Spoelstra, J. Lankelma
Primary Institution: Free University Hospital
Hypothesis
Does Cremophor EL affect drug accumulation and cytotoxicity in multidrug-resistant cancer cells?
Conclusion
Cremophor EL is effective in reversing multidrug resistance in human myeloma cells and may have clinical implications.
Supporting Evidence
- Cremophor EL significantly stimulated doxorubicin and daunorubicin accumulation in resistant cells.
- At higher concentrations, Cremophor EL showed more pronounced effects on drug cytotoxicity.
- Cremophor EL reversed doxorubicin resistance in myeloma cells with a low resistance index.
- Drug accumulation differences were more pronounced for daunorubicin than for doxorubicin in resistant cells.
- Cremophor EL's effects on drug localization may explain its ability to reverse resistance.
Takeaway
Cremophor EL helps cancer cells take in more medicine, making the medicine work better against the cancer.
Methodology
In vitro experiments were conducted on human tumor cell lines to assess the effects of Cremophor EL on drug accumulation and cytotoxicity.
Limitations
The study primarily focuses on specific cell lines and may not fully represent all types of cancer.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website